Drug Repurposing Market Analysis Through 2030: Market Size, Growth Trends And Industry Outlook
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Drug Repurposing Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The drug repurposing market has experienced substantial growth in recent years. It will grow from $37.38 billion in 2025 to $40.95 billion in 2026 at a compound annual growth rate (CAGR) of 9.6%. This historical expansion can be attributed to several factors, including the significant cost and time involved in traditional drug discovery, an increasing number of failed drug candidates, the rising incidence of chronic and rare diseases, a scarcity of therapeutic options for emerging diseases, and the early integration of computational approaches for drug repositioning.
The drug repurposing market size is expected to show robust expansion in the near future. It is projected to increase to $58.33 billion in 2030, driven by a compound annual growth rate (CAGR) of 9.2%. This projected growth can be attributed to the integration of AI and machine learning in drug repurposing, a surge in investment within biotech and pharma research, the expanding capabilities of contract research organizations (CROs), an increasing demand for affordable therapies, and supportive regulatory environments for repurposed drug approvals. Significant developments anticipated during this forecast period include an intensified focus on phenotypic and target-based screening, the rising adoption of structure-based drug repositioning, advancements in identifying off-target activities, the extended application of drug repurposing for rare and infectious diseases, and the shortening of drug development timelines through the utilization of existing molecules.
Get A Free Sample Report With In-Depth Market Insights:
Drug Repurposing Market Growth Factors Behind Sustained Expansion
The rising incidence of neurodegenerative diseases is anticipated to boost the expansion of the drug repurposing market in the future. Neurodegenerative diseases represent a collection of disorders characterized by the progressive loss of structure or function in neurons, eventually resulting in their death. The increase in neurodegenerative conditions, such as alzheimer’s dementia, is attributed to extended life expectancy, as aging is the primary risk factor contributing to the gradual decline of neuronal function over time. Drug repurposing assists in combating neurodegenerative diseases by identifying existing drugs with established safety profiles that can be re-directed to target specific disease pathways, thereby accelerating the development of effective treatments. For instance, in March 2023, according to the Alzheimer’s Association, a US-based nonprofit voluntary health organization, approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with forecasts indicating an increase to 13.8 million by 2060. Therefore, the growing prevalence of neurodegenerative diseases is a key driver for the growth of the drug repurposing market.
Drug Repurposing Market Breakdown By Product Type And Application
The drug repurposing market covered in this report is segmented –
1) By Type: Disease-Centric, Target-Centric, Drug-Centric
2) By Drug Molecules: Biologics, Small Molecule
3) By Therapeutic Area: Oncology, Neurology, Infectious Diseases, Cardiovascular Diseases, Autoimmune Disorders
4) By Route Of Administration: Oral, Intravenous, Topical, Inhalation, Intramuscular
5) By End-User: Pharmaceutical Companies, Research And Academic Institutes, Contract Research Organizations
Subsegments:
1) By Disease-Centric: Phenotypic Screening, Epidemiological Analysis, Clinical Observation-Based Repurposing
2) By Target-Centric: Protein Target Modulation, Pathway Modulation, Biomarker-Based Targeting
3) By Drug-Centric: Off-Target Activity Identification, Structure-Based Drug Repositioning, Adverse Effect-Based Repurposing
Drug Repurposing Market Industry Trends Fueling Future Revenue Growth
Leading firms within the drug repurposing market are concentrating on creating sophisticated technologies, specifically artificial intelligence (AI)-powered drug-protein interaction modeling, to speed up the discovery of novel therapeutic applications for existing medications. This particular modeling approach, driven by AI, utilizes artificial intelligence and machine learning to forecast drug interactions with proteins throughout the human proteome, employing vast datasets to improve both precision and reliability. An example of this is Cosmos Health Inc., a US-based healthcare company, which introduced Cloudscreen 2.0, an advanced AI platform for drug repurposing, in July 2025. This system represents a new generation, built to handle datasets more than 100 times larger than previous versions, facilitating a thorough analysis of drug-protein interactions. The platform incorporates mutagenesis data and tools for examining disordered proteins, allowing it to target conditions like cancer, obesity, and diabetes. Furthermore, scalable processing is enabled by graphics processing unit (GPU)-based cloud computing, establishing the platform as a vital advancement in speeding up research and development for drug repurposing across diverse therapeutic fields.
Drug Repurposing Market Company Landscape And Competitive Strategy
Major companies operating in the drug repurposing market are F. Hoffmann-La Roche Ltd , Bayer AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., UCB S.A., Eisai Co Ltd., Celltrion Inc., Evotec SE, BenevolentAI Limited, Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Pharnext S.A., Healx Ltd., Algernon Pharmaceuticals Inc., BioXcel Therapeutics Inc.
View The Full Drug Repurposing Market Report:
Drug Repurposing Market Global Footprint: Which Region Leads The Market?
North America was the largest region in the drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
